GlassScriptPhysician profile
Cleofas Pena
NPI 1285863381
$10,880.30
in general payments reported to CMS, 2019-2025
32 companies · $2,335 in 2025
The $2,335 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,602 · 2022: $2,088 · 2023: $2,511 · 2024: $2,345 · 2025: $2,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,018 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,018.35 |
| Education | $172.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,381.07 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $1,233.73 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,152.02 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,065.57 | 2021-2025 | Cuvitru, Takhzyro, Glassia |
| Biocryst US Sales Co., LLC | $600.72 | 2021-2025 | Orladeyo |
| Amgen INC. | $589.37 | 2021-2025 | Tezspire |
| Csl Behring | $526.02 | 2021-2025 | Haegarda, Hizentra, Andembry |
| Novartis Pharmaceuticals Corporation | $438.98 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $420.89 | 2023-2025 | |
| Genzyme Corporation | $291.71 | 2021-2025 | |
| Genentech USA, INC. | $281.46 | 2021-2024 | Xolair |
| Pharming Healthcare, INC. | $263.07 | 2021-2025 | Ruconest |
| Optinose US, INC. | $239.82 | 2021-2025 | |
| Abbvie INC. | $229.69 | 2022-2025 | |
| Octapharma USA, INC. | $212.80 | 2022-2025 | Cutaquig, Panzyga |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $204.73 | 2021-2025 | Xembify |
| Pfizer INC. | $144.01 | 2022-2025 | |
| Ars Pharmaceuticals Operations, INC. | $119.55 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $67.16 | 2025 | Nemluvio |
| Alk-Abello, INC | $66.28 | 2023-2025 | Grastek, Ragwitek, Odactra |
| Leo Pharma INC. | $50.20 | 2022 | |
| Mylan Specialty L.P. | $43.81 | 2022-2023 | Yupelri |
| Merck Sharp & Dohme LLC | $42.66 | 2021-2023 | |
| Paratek Pharmaceuticals, INC. | $37.63 | 2025 | Xhance |
| Blueprint Medicines Corporation | $27.24 | 2023 | Ayvakit |
| Ionis Pharmaceuticals, INC. | $26.22 | 2025 | Dawnzera |
| Organon LLC | $24.18 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.96 | 2023 | Stiolto Respimat, Spiriva Respimat |
| Sanofi Pasteur INC. | $21.25 | 2024 | |
| Uswm, LLC | $21.24 | 2021 | |
| Incyte Corporation | $20.35 | 2021 | |
| Phadia US INC. | $12.91 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cleofas Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.